After 10 Years, US FDA ‘Additional Conditions’ Proposed Rule Offers ‘Novel Switch’ Pathway
Executive Summary
Publication of "ACNU" proposed rule wasn’t reached in straight line and featured coining another term with more of a regulatory sound, “NSURE,” and detours on explaining where the agency wouldn’t steer OTC drug manufacturing and marketing.
You may also be interested in...
J&J's Manoj Raghunandanan On Becoming A 'Digital First' Consumer Health Company
“We want to make sure digital is embedded into every aspect of our business, from R&D and supply chain, to marketing and finance,” says Johnson & Johnson's president of global self-care and consumer experience organization Manoj Raghunandanan in this exclusive interview.
Along With All NDAs Submitted To US FDA In FY2023, Costs For OTC Switch Proposals Increase
Agency publishes Prescription Drug User Fee Act rates for FY2023, the first of five covered in reauthorization of program Congress approved on 30 September as legislation added to a continuing resolution to fund federal agencies through 16 December.
US OTC Birth Control NDA Could Debut ‘Additional Conditions for Nonprescription Use’ Labeling
HRA didn't have time to incorporate into its switch NDA instructions stated in proposed ACNU rule published in June, but the firm, which worked with Ibis Reproductive Health on proposal, had time to plumb a draft guidance FDA published in 2018 on novel switches.